UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 10, 2008

ACCENTIA BIOPHARMACEUTICALS, INC.

(Exact name of Registrant as Specified in its Charter)

Florida	000-51383	04-3639490
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	(I.R.S. Employer Identification No.)

324 South Hyde Park Ave., Suite 350

Tampa, Florida 33606

(Address of Principal Executive Offices; Zip Code)

Registrant’s telephone number, including area code: (813) 864-2554

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2-(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ACCENTIA BIOPHARMACEUTICALS, INC.

FORM 8-K

Item 2.05 Costs Associated With Exit Or Disposition Activities.

Effective as of November 10, 2008, concurrent with filing for reorganization under Chapter 11 of the Bankruptcy Code, Accentia Biopharmaceuticals, Inc. (the “Company”) ceased operations in its Accentia Pharmaceuticals subsidiary in order to focus available recourses on core business operations, including drug development. This action resulted in the termination of 26 employees. Excluding any non-cash accounting adjustments, such as impairments or charge-offs, which have not yet been determined and which may result from the cessation of the business, cash expenditures directly associated with the exit activities are anticipated to be approximately $0.1 million which are primarily as a result of one-time severance payments and costs of wind-up activities.

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunder duly authorized.

ACCENTIA BIOPHARMACEUTICALS, INC.
By:	/s/ Samuel S. Duffey
	Samuel S. Duffey
	General Counsel

November 14, 2008